IP Library Granted Patent US 9,815,895
Granted Patent B2
US 9,815,895 · App. 13/934,271 · Granted Nov 14, 2017

Methods of reducing basophil levels

Inventors: Masamichi Koike (West Windsor, NJ); George L. Spitalny (Yardley, PA); Alistair Wheeler (Northborough, MA); Barbara White (Finksburg, MD)
Assignees: BIOWA, INC.; ASTRAZENECA AB
C07K16/28C07K7/08C07K16/2866A61K2039/505C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,815,895
App. No.
13/934,271
Granted
Nov 14, 2017
Kind
B2
Abstract

The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.

Claims (6)

1. A method of reducing the numbers of peripheral blood basophils in an asthmatic subject comprising parenterally administering to said subject in need thereof between 0.01 to 0.25 mg/kg of an anti-Interleukin-5 receptor (IL-5R) antibody comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO:3 and comprising an immunoglobulin Fc region comprising no fucose, wherein the administration of the antibody reduces the number of peripheral blood basophils from the asthmatic subject's circulation by 5 to 70 basophils/mm 3 by 24 hours post-administration.

2. The method of claim 1 , wherein the reduction of basophils is reversible.

3. The method of claim 1 , wherein the numbers of basophils are reduced to a level that is less than 9 basophils/mm 3 .

4. The method of claim 1 , wherein there is a post-administration reduction in absolute basophil count of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at least 70 basophils/mm 3 .

5. The method of claim 1 , wherein said subject's pre-administration absolute basophil count is between 5 and 500 basophils/mm 3 .

6. The method of claim 1 , wherein said subject's pre-administration absolute basophil count is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 50, at least 60, at least 70, at least 100, at least 200, at least 300, at least 400, or at least 500 basophils/mm 3 .

Assignments (5)
CHANGE OF NAME Recorded Dec 3, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 051171/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: BIOWA INC
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 049275/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: MEDIMMUNE, LLC
To: ASTRAZENECA AB
Reel/Frame 039258/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2014
From: KOIKE, MASAMICHI; SPITALNY, GEORGE L.; WHEELER, ALISTAIR
To: BIOWA
Reel/Frame 032983/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2014
From: WHITE, BARBARA
To: MEDIMMUNE, LLC
Reel/Frame 032983/0929 →
Continuity (7)
Continuation 13177221 · Jul 6, 2011
Continuation 12600017
Provisional Application 60924422 · May 14, 2007
Provisional Application 60924832 · Jun 1, 2007
Provisional Application 60935005 · Jul 20, 2007
Provisional Application 61064612 · Mar 14, 2008
Related Publication 20140004109A1 · Jan 2, 2014